At the conclusion of this activity, participants should be able to:
• Review and discuss novel medical and surgical approaches to glaucoma management
• Identify new clinical advances and discoveries in glaucoma care
• Review and discuss current diagnostic tools for glaucoma
Registration for the 31st Annual Glaucoma Symposium will be available soon
30th Annual Glaucoma Symposium Meeting Highlights
From Course Director Jullia Rosdahl MD PhD
Divakar Gupta MD
Dr. Divakar Gupta showed how the new field of Bioinformatics has and will continue to shape the course for medicine and ophthalmology.
Related reference: Characterizing the “POAGome”: A bioinformatics-driven approach to primary open-angle glaucoma. Danford et al. Prog Retin Eye Res 2017 May; 58:89-114.
Keynote: Jonathan Myers MD
Dr. Jonathan Myers, currently Professor at Wills Eye at the University of Pennsylvania, is a Duke Glaucoma Fellow Alum. His Keynote talk included a comprehensive summary of many of the seminal epidemiologic studies on glaucoma, and he showed how those data can help us work to prevent glaucoma blindness in our patients.
Related reference: Glaucoma Blindness at the end of life. Mokles et al. Acta Ophthalmol 2017 Feb; 95(1):10-11.
Sharon Freedman MD
Dr. Sharon Freedman described the effect of glaucoma surgery on motility and offered practical tips on preventing and managing diplopia with glaucoma tube surgery.
Related reference: Motility disturbances in the tube versus trabeculectomy study during the first year of follow-up. Rauscher et al. Am J Ophthalmol 2009 Mar; 147(3):458-66.
Jill Koury MD
The recent shortages of dorzolamide-timolol prompted Dr. Jill Koury to try to understand the complex system that gets bottles of eye drops from the pharmacies to our patients, which she shared in her thorough summary of her findings.
David Fleischman MD
Dr. David Fleischman is another Duke Glaucoma Fellow Alum who came as a Visiting Speaker from across town at UNC-Kittner Eye. His talk on the role of cerebro-spinal fluid pressure on glaucoma summarized this fascinating scientific work. He also highlighted the important impact of Dr. Rand Allingham on this work and on his own career development, a sentiment shared by many at Duke and in the field of glaucoma.
Reference: The role of cerebrospinal fluid pressure in glaucoma and other ophthalmic diseases: A review. Fleischman and Allingham. Saudi J Ophthalmol 2013 Apr; 27(2):97-106.
We held our first Glaucoma Debate, moderated by Dr. Kelly Muir and featuring three of our Glaucoma Fellows (Ayan Chattergee MD, Katy Liu MD PhD, and Swarup Swaminathan MD) who were supported by three of our Duke Glaucoma Faculty (Leon Herndon MD, Stuart McKinnon MD PhD, and Sanjay Asrani MD). They debated the question: What is your first-line therapy for a 55-year-old woman with newly diagnosed moderate-stage Primary Open Angle Glaucoma? Prostaglandin Analogues (Dr. Lui), Selective Laser Trabeculoplasty (Dr. Swaminathan), or Minimally Invasive Glaucoma Surgery (Dr. Chattergee). The winner was the fellow who convinced more of the audience to change their minds in favor of their argued therapy. While all of the fellows gave strong arguments and generated support from the audience, it was Dr. Chattergee who took home the prize, convincing 9% of the audience with his argument for MIGS (up from 0% at baseline). Glaucoma Fellow Dr. Brian Stagg, rounded out this session with a discussion of the cost effectiveness of the treatment options, summarizing the literature and offering patient-specific considerations.
Atalie Thompson MD MPH
Glaucoma Fellow Dr. Atalie Thompson kicked off the afternoon presenting a case of Pseudoexfolation Glaucoma requiring complex glaucoma and cataract surgical management.
Sayoko Moroi MD PhD
Dr. Sayoko Moroi, currently Professor at Kellogg Eye at the University of Michigan, is a Duke Glaucoma Fellow Alum. In her Keynote talk, she reviewed population-based glaucoma studies and discussed how limitations of our current ways of assessing clinical metrics in glaucoma (IOP, optic nerve changes, visual field changes) have influenced her research goal of using genetic information to improve diagnostic and therapeutic outcomes for people with glaucoma.
Divakar Gupta MD
Dr. Divakar Gupta finished out the day with an overview of glaucoma medications, with an historical perspective and covering medications we have significant experience with as well as the new classes of glaucoma medications that have become available this year (slides prepared by Dr. Pratap Challa who was unable to present them). Our visiting faculty, as well as Duke faculty, Drs. Thomas Hunter, Henry Tseng, and Carol Ziel, shared their experiences on a panel moderated by Dr. Gupta.
Related reference: New pharmacotherapy for the treatment of glaucoma. Schehlein, Novack, Robin. Expert Opin Phamacother 2017 Dec; 18(18):1939-1946